吲哚胺2,3-二氧化酶在病毒性肝炎中的研究进展  

Indoleamine 2,3-dioxygenase on patients with viral hepatitis

作　　者：卢小芳[1] 王悦芬[2] 王彦刚[3] 

机构地区：[1]河北医科大学,河北石家庄050000 [2]北京中医药大学附属东直门医院脑病科 [3]河北医科大学附属河北省中医院消化内科

出　　处：《胃肠病学和肝病学杂志》2014年第12期1387-1389,共3页Chinese Journal of Gastroenterology and Hepatology

摘　　要：病毒性肝炎具有强传染性、高流行性,其传播途径复杂、发病率高、对人体危害性大,已成为社会普遍关注的一类重要的传染性疾病。随着科学社会的进步,目前对于肝炎的治疗有一定的进展,主要应用干扰素、核苷类、基因疗法等抗病毒药物,但这些治疗适用范围局限,副作用大,易产生病毒变异和耐药现象,使病情反复,治疗出现"瓶颈"。近几年,吲哚胺2,3-二氧化酶(indoleamine 2,3-dioxygenase,IDO)在病毒性肝炎中的作用日益受到关注,其与肝炎患者免疫耐受、病毒的复制、肝细胞的损伤程度密切相关。这将为病毒性肝炎的治疗提供新的思路。本文针对IDO在病毒性肝炎中的进展作一概述。Viral hepatitis as an important infectious disease has received much more attention for strong infectivity, high popularity, complex routes of transmission and high incidence. With the progress of science and society, the treat- ment of hepatitis has made a certain progress including the application of interferon, nucleoside and gene therapy. How- ever, these treatments have been limited for side effects, being easy to produce the virus mutation and resistance phe- nomenon, these may make the illness repeated. At present, treatment appears the ＂ bottleneck＂. In recent years, in- doleamine 2, 3-dioxygenase （IDO） has received more attention in the viral hepatitis. It＇ s related to immune tolerance, virus replication and the damage degree of liver cells. It may provide a novel treatment for viral hepatitis. This article will review the progress of IDO in viral hepatitis.

关 键 词：病毒性肝炎 吲哚胺2 3-二氧化酶 炎症反应 免疫抑制 IDO抑制剂 

分 类 号：R512.6[医药卫生—内科学]